Subgroup analyses also showed that OS was more favorable in those without PD-L1 expression than in those with PD-L1 expression among patients with TNM stage I/II disease (median OS: 103 months vs. 55 months, p = 0.036), TNM stage III/IV disease (median OS: 58 months vs. 26 months, p = 0.005), and tumor stage pT3 (median OS: 96 months vs. 26 months, p = 0.005), but not in patients with tumor stage pT1, pT2, or pT4 or node metastasis (p > 0.05) (Figure 5). This evidence concerns the gene CD274 and neoplasm.